Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02081950Phase 1Completed

A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions

Role: lead

NCT02232802Phase 1Completed

Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.

Role: lead

NCT02668588Phase 2Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Role: lead

NCT01754285Phase 2Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Role: lead

All 4 trials loaded